News: Transdermal E2 gel offers efficacy, flexibility to women with vasomotor symptoms
Compared with placebo, all three doses of transdermal E2 gel significantly reduced from baseline the frequency and severity of vasomotor symptoms in postmenopausal women.
Researchers tested three doses (1.0, 0.5, and 0.25 mg/day) of transdermal estradiol (E2) gel 0.1%, consisting of 1 mg of E2 per 1 g of transdermal gel, and found that compared with placebo, all three doses significantly reduced from baseline the frequency and severity of vasomotor symptoms in postmenopausal women as early as week 2 of treatment.
The 12-week study involved 488 postmenopausal women. All three doses also significantly improved vulvar and vaginal atrophy, when compared with placebo. Improvements were maintained throughout treatment. Of the 58 women who discontinued participation in the study prematurely, only 13 did so due to inefficacy; nine did so due to adverse events.
The researchers noted that the greatest improvements were seen with the highest dose, but that the availability of three doses allows for up-and-down titration and compliance with current recommendations to use estrogen, as part of hormone therapy, at the lowest effective dose.
Single iron infusion in late pregnancy significantly reduces anemia risk
January 22nd 2025A recent study found that a single dose of intravenous iron in the third trimester is superior to oral iron in reducing anemia rates in pregnant women, ensuring better outcomes for mother and baby.
Read More
Study highlights need for interventions to prevent postpartum smoking relapse
January 21st 2025Smoking cessation during pregnancy not only reduces pregnancy complications but also lowers the risk of relapse and new smoking initiation in the first postpartum year, according to a recent study.
Read More
